Literature DB >> 22002321

Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity.

Klaus Pors1, Paul M Loadman, Steven D Shnyder, Mark Sutherland, Helen M Sheldrake, Meritxell Guino, Konstantinos Kiakos, John A Hartley, Mark Searcey, Laurence H Patterson.   

Abstract

The identification of an agent that is selectively activated by a cytochrome P450 (CYP) has the potential for tissue specific dose intensification as a means of significantly improving its therapeutic value. Towards this goal, we disclose evidence for the pathway of activation of a duocarmycin analogue, ICT2700, which targets CYP1A1 for biological activity.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22002321     DOI： 10.1039/c1cc15638a

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN： 1359-7345            Impact factor:   6.222


  9 in total

1.  A five-membered lactone prodrug of CBI-based analogs of the duocarmycins.

Authors:  Mika Uematsu; Daniel M Brody; Dale L Boger
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

2.  Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.

Authors:  Amanda L Wolfe; Katharine K Duncan; Nikhil K Parelkar; Douglas Brown; George A Vielhauer; Dale L Boger
Journal:  J Med Chem       Date:  2013-05-10       Impact factor: 7.446

Review 3.  Cytochrome P450-activated prodrugs.

Authors:  Paul R Ortiz de Montellano
Journal:  Future Med Chem       Date:  2013-02       Impact factor: 3.808

4.  A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: hydrophobic-binding-driven bonding.

Authors:  Amanda L Wolfe; Katharine K Duncan; James P Lajiness; Kaicheng Zhu; Adam S Duerfeldt; Dale L Boger
Journal:  J Med Chem       Date:  2013-08-29       Impact factor: 7.446

5.  Cytochrome P450 Binding and Bioactivation of Tumor-Targeted Duocarmycin Agents.

Authors:  Aaron G Bart; Goreti Morais; Venu R Vangala; Paul M Loadman; Klaus Pors; Emily E Scott
Journal:  Drug Metab Dispos       Date:  2021-10-04       Impact factor: 3.922

6.  Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors.

Authors:  Vasilis P Androutsopoulos; Ioannis Spyrou; Achilles Ploumidis; Alexandros Eystathios Papalampros; Michalis Kyriakakis; Demetrios Delakas; Demetrios A Spandidos; Aristidis M Tsatsakis
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

7.  Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer.

Authors:  Daniela Presa; Syed A Khurram; Amir Z A Zubir; Sneha Smarakan; Patricia A Cooper; Goreti R Morais; Maria Sadiq; Mark Sutherland; Paul M Loadman; James McCaul; Steven D Shnyder; Laurence H Patterson; Klaus Pors
Journal:  Sci Rep       Date:  2021-09-23       Impact factor: 4.379

Review 8.  Intratumoural Cytochrome P450 Expression in Breast Cancer: Impact on Standard of Care Treatment and New Efforts to Develop Tumour-Selective Therapies.

Authors:  Smarakan Sneha; Simon C Baker; Andrew Green; Sarah Storr; Radhika Aiyappa; Stewart Martin; Klaus Pors
Journal:  Biomedicines       Date:  2021-03-12

Review 9.  Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors.

Authors:  Mauricio Rodriguez-Torres; Alison L Allan
Journal:  Clin Exp Metastasis       Date:  2015-10-07       Impact factor: 5.150
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.